Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Thomas

Showing results (11-20 of 217) with videos related to

Pageof 22
Sort By:
The Lancet. Oncology|November 8, 2016
Sarcoma and germ-line DICER1 mutations - Authors' replyMandy L Ballinger, David M Thomas,
Brain Research|July 1, 2005
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicityDavid M Thomas, Donald M Kuhn
Clinical Sarcoma Research|May 17, 2012
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumoursFergal C Kelleher, David M Thomas
European Journal of Human Genetics : EJHG|August 12, 2024
POT1 clinical risk management is an open questionMandy L Ballinger, David M Thomas
Molecular & Cellular Oncology|June 17, 2016
The life history of neochromosomes revealedAnthony T Papenfuss, David M Thomas
Current Oncology Reports|April 20, 2011
Novel approaches to treatment of leiomyosarcomasIan M Collins, David M Thomas
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 15, 2016
Diagnosis and Management of Hereditary SarcomaDavid M Thomas, Mandy L Ballinger
Journal of Surgical Oncology|October 23, 2014
Etiologic, environmental and inherited risk factors in sarcomasDavid M Thomas, Mandy L Ballinger
The Journal of Pharmacology and Experimental Therapeutics|February 19, 2005
Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicityDavid M Thomas, Donald M Kuhn
Journal of Neurochemistry|February 3, 2005
Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamineDavid M Thomas, Donald M Kuhn
Pageof 22

Showing results (11-20 of 217) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|November 8, 2016
Sarcoma and germ-line DICER1 mutations - Authors' replyMandy L Ballinger, David M Thomas,
Brain Research|July 1, 2005
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicityDavid M Thomas, Donald M Kuhn
Clinical Sarcoma Research|May 17, 2012
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumoursFergal C Kelleher, David M Thomas
European Journal of Human Genetics : EJHG|August 12, 2024
POT1 clinical risk management is an open questionMandy L Ballinger, David M Thomas
Molecular & Cellular Oncology|June 17, 2016
The life history of neochromosomes revealedAnthony T Papenfuss, David M Thomas
Current Oncology Reports|April 20, 2011
Novel approaches to treatment of leiomyosarcomasIan M Collins, David M Thomas
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 15, 2016
Diagnosis and Management of Hereditary SarcomaDavid M Thomas, Mandy L Ballinger
Journal of Surgical Oncology|October 23, 2014
Etiologic, environmental and inherited risk factors in sarcomasDavid M Thomas, Mandy L Ballinger
The Journal of Pharmacology and Experimental Therapeutics|February 19, 2005
Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicityDavid M Thomas, Donald M Kuhn
Journal of Neurochemistry|February 3, 2005
Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamineDavid M Thomas, Donald M Kuhn
Pageof 22